Compare
NeoGenomics Inc vs UL Solutions Inc. vs Incyte Corp vs Icon PLC
| Latest fiscal year | NeoGenomics Inc NEO | UL Solutions Inc. ULS | Incyte Corp INCY | Icon PLC ICLR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $727.33M | $3.05B | $5.14B | $8.25B |
| Revenue growth (YoY) | +10.1% | +6.4% | +21.2% | +0.8% |
| Gross margin | 43.2% | 49.5% (computed) | 92.8% (computed) | n/a |
| Operating margin | -15.9% | 17.1% | 29.5% | 5.4% |
| Net margin | -14.9% | 10.6% | 25.0% | 2.8% |
| Net income | -$108.03M | $325.00M | $1.29B | $229.34M |
| EPS (Diluted) | n/a | $1.60 | $6.41 | $2.90 |
| Operating cash flow | $5.23M | $600.00M | $1.41B | $1.04B |
| Free cash flow | -$21.78M | $403.00M | n/a | $861.99M |
| Cash & equivalents | $159.62M | $295.00M | $3.10B | $647.29M |
| Total assets | $1.36B | $2.92B | $6.96B | $16.27B |
| Total liabilities | $523.27M | $1.63B | $1.79B | $7.08B |
| Shareholders' equity | $836.56M | $1.29B | $5.17B | $9.19B |
| Return on year-end equity | -12.9% | 25.1% | 24.9% | 2.5% |
| Shares outstanding | 128.15M | 201.03M | 198.46M | 76.57M |
Revenue, most recent five fiscal years
| Fiscal year | NeoGenomics Inc | UL Solutions Inc. | Incyte Corp | Icon PLC |
|---|---|---|---|---|
| Latest | $727.33M Ended 2025-12-31 | $3.05B Ended 2025-12-31 | $5.14B Ended 2025-12-31 | $8.25B Ended 2025-12-31 |
| 1 year earlier | $660.57M Ended 2024-12-31 | $2.87B Ended 2024-12-31 | $4.24B Ended 2024-12-31 | $8.19B Ended 2024-12-31 |
| 2 years earlier | $591.64M Ended 2023-12-31 | $2.68B Ended 2023-12-31 | $3.70B Ended 2023-12-31 | $8.05B Ended 2023-12-31 |
| 3 years earlier | $509.73M Ended 2022-12-31 | $2.52B Ended 2022-12-31 | $3.39B Ended 2022-12-31 | $7.74B Ended 2022-12-31 |
| 4 years earlier | $484.33M Ended 2021-12-31 | n/a | $2.99B Ended 2021-12-31 | $5.48B Ended 2021-12-31 |